title: Expression of type I interferon receptor as a predictor of clinical response to interferon-alpha therapy of gastrointestinal cancers.
abstract: Interferon (IFN) is used in the treatment of many malignancies and viral disorders. We recently reported a significant correlation between the efficacy of IFN-alpha combined with chemotherapy in the treatment of advanced hepatocellular carcinoma (HCC) and IFN-alpha/type I IFN receptor (IFNAR2) expression. It is possible that the expression of IFNAR2 in gastrointestinal cancerous tissue, apart from HCC, may predict the efficacy of IFN-alpha combination therapy. We investigated the expression of IFNAR2 in 100 gastrointestinal cancerous tissues. IFNAR2 expression was examined using immunohistochemistry, in surgically resected tissue samples (20 esophageal, 20 gastric, 20 colorectal, 20 cholangiocarcinoma, and 20 pancreatic samples). The expression rate of IFNAR2 was 35.0% (7/20), 25.0% (5/20), 20.0% (4/20), 45.0% (9/20), and 25.0% (5/20) in esophageal, gastric cancer, colorectal, cholangiocarcinoma and pancreatic cancer samples, respectively. In our previous report, the expression rate of IFNAR2 in HCC samples was 64.8% (59/91). Thus, the expression rates of IFNAR2 in the five types of gastrointestinal cancers tested here were low, compared with HCC. The clinical efficacy of IFN-alpha mono- or combination therapies in patients with gastrointestinal neoplasms is expected to be lower than in patients with HCC based on the expression level of IFNAR2.
authors.affiliation: Department of Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
authors.forename: Hideo
authors.initials: H
authors.lastname: Ota
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Nagano
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Doki
authors.forename: Mitsugu
authors.initials: M
authors.lastname: Sekimoto
authors.forename: Motoi
authors.initials: M
authors.lastname: Kondo
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Wada
authors.forename: Masato
authors.initials: M
authors.lastname: Nakamura
authors.forename: Takehiro
authors.initials: T
authors.lastname: Noda
authors.forename: Bazarragchaa
authors.initials: B
authors.lastname: Damdinsuren
authors.forename: Shigeru
authors.initials: S
authors.lastname: Marubashi
authors.forename: Atsushi
authors.initials: A
authors.lastname: Miyamoto
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Takeda
authors.forename: Keizo
authors.initials: K
authors.lastname: Dono
authors.forename: Koji
authors.initials: K
authors.lastname: Umeshita
authors.forename: Shoji
authors.initials: S
authors.lastname: Nakamori
authors.forename: Kenichi
authors.initials: K
authors.lastname: Wakasa
authors.forename: Masato
authors.initials: M
authors.lastname: Sakon
authors.forename: Morito
authors.initials: M
authors.lastname: Monden
mesh_terms: D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D016898:Interferon-alpha / Q000627:therapeutic use*; D008565:Membrane Proteins / Q000032:analysis*; D011379:Prognosis; D053633:Receptor, Interferon alpha-beta; D017471:Receptors, Interferon / Q000032:analysis*; D016896:Treatment Outcome
chemical_list: C508033:IFNAR2 protein, human; D016898:Interferon-alpha; D008565:Membrane Proteins; D017471:Receptors, Interferon; D053633:Receptor, Interferon alpha-beta